(Total Views: 141)
Posted On: 08/22/2024 3:52:34 PM
Post# of 90
NetworkNewsBreaks – PaxMedica Inc. (PXMD) Committed to Global Health, Potential Positive Impact of PAX-101
PaxMedica (OTC: PXMD), a biopharmaceutical company specializing in neurological disorder treatments, is preparing to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration for suramin to treat Human African Trypanosomiasis (“HAT”). “In April 2024, PaxMedica underscored its commitment to global health by responding to an urgent request from Malawi for an emergency release of suramin, demonstrating its dedication to advancing healthcare solutions. PaxMedica will have a crucial Type C meeting with the FDA, pivotal to the progress of PAX-101, its leading drug candidate for autism treatment, within the regulatory framework… This meeting is a significant event for PaxMedica, as it aims to align with the FDA on PAX-101, an intravenous formulation of suramin that could potentially treat conditions like HAT and Autism Spectrum Disorder (‘ASD’),” a recent article reads. “Successfully navigating this meeting could advance clinical trials and the approval process, crucial for addressing HAT, a neglected tropical disease, and ASD, affecting millions worldwide. PaxMedica’s recent efforts, like providing for HAT treatment in Malawi, highlight the company’s commitment to global health and the potential positive impact of PAX-101 on healthcare.”
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://nnw.fm/PXMD
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
PaxMedica (OTC: PXMD), a biopharmaceutical company specializing in neurological disorder treatments, is preparing to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration for suramin to treat Human African Trypanosomiasis (“HAT”). “In April 2024, PaxMedica underscored its commitment to global health by responding to an urgent request from Malawi for an emergency release of suramin, demonstrating its dedication to advancing healthcare solutions. PaxMedica will have a crucial Type C meeting with the FDA, pivotal to the progress of PAX-101, its leading drug candidate for autism treatment, within the regulatory framework… This meeting is a significant event for PaxMedica, as it aims to align with the FDA on PAX-101, an intravenous formulation of suramin that could potentially treat conditions like HAT and Autism Spectrum Disorder (‘ASD’),” a recent article reads. “Successfully navigating this meeting could advance clinical trials and the approval process, crucial for addressing HAT, a neglected tropical disease, and ASD, affecting millions worldwide. PaxMedica’s recent efforts, like providing for HAT treatment in Malawi, highlight the company’s commitment to global health and the potential positive impact of PAX-101 on healthcare.”
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://nnw.fm/PXMD
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
